Literature DB >> 17583734

Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity.

Christian S Parry1, Jack Gorski, Lawrence J Stern.   

Abstract

We describe structural studies of the human leukocyte antigen DR52a, HLA-DRA/DRB3*0101, in complex with an N-terminal human platelet integrin alphaII(B)betaIII glycoprotein peptide which contains a Leu/Pro dimorphism. The 33:Leu dimorphism is the epitope for the T cell directed response in neonatal alloimmune thrombocytopenia and post-transfusion purpura in individuals with the alphaII(B)betaIII 33:Pro allele, and defines the unidirectional alloimmune response. This condition is always associated with DR52a. The crystallographic structure has been refined to 2.25 A. There are two alphabeta heterodimers to the asymmetric unit in space group P4(1)2(1)2. The molecule is characterized by two prominent hydrophobic pockets at either end of the peptide binding cleft and a deep, narrower and highly charged P4 opening underneath the beta 1 chain. Further, the peptide in the second molecule displays a sharp upward turn after pocket P9. The structure reveals the role of pockets and the distinctive basic P4 pocket, shared by DR52a and DR3, in selecting their respective binding peptide repertoire. We observe an interesting switch in a residue from the canonically assigned pocket 6 seen in prior class II structures to pocket 4. This occludes the P6 pocket helping to explain the distinctive "1-4-9" peptide binding motif. A beta57 Asp-->Val substitution abrogates the salt-bridge to alpha76 Arg and along with a hydrophobic beta37 is important in shaping the P9 pocket. DRB3*0101 and DRB1*0301 belong to an ancestral haplotype and are associated with many autoimmune diseases linked to antigen presentation, but whereas DR3 is susceptible to type 1 diabetes DR52a is not. This dichotomy is explored for clues to the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583734     DOI: 10.1016/j.jmb.2007.05.025

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  19 in total

1.  Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.

Authors:  Jens Kjeldsen-Kragh; Dean A Fergusson; Mette Kjaer; Lani Lieberman; Andreas Greinacher; Michael F Murphy; James Bussel; Tamam Bakchoul; Stacy Corke; Gérald Bertrand; Dick Oepkes; Jillian M Baker; Heather Hume; Edwin Massey; Cecile Kaplan; Donald M Arnold; Shoma Baidya; Greg Ryan; Helen F Savoia; Denise Landry; Nadine Shehata
Journal:  Blood Adv       Date:  2020-07-28

2.  T cell responses to human platelet antigen-1a involve a unique form of indirect allorecognition.

Authors:  Maria Therese Ahlen; Anne Husebekk; Ida Løken Killie; Bjørn Skogen; Tor Brynjar Stuge
Journal:  JCI Insight       Date:  2016-09-08

3.  HLA-DRB3*01:01 exhibits a dose-dependent impact on HPA-1a antibody levels in HPA-1a-immunized women.

Authors:  Jens Kjeldsen-Kragh; Thomas L Titze; Benedicte Alexandra Lie; John T Vaage; Mette Kjær
Journal:  Blood Adv       Date:  2019-04-09

4.  A short HLA-DRA isoform binds the HLA-DR2 heterodimer on the outer domain of the peptide-binding site.

Authors:  Hengameh Shams; Jill A Hollenbach; Atsuko Matsunaga; Mohammad R K Mofrad; Jorge R Oksenberg; Alessandro Didonna
Journal:  Arch Biochem Biophys       Date:  2022-02-24       Impact factor: 4.013

5.  Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Authors:  Rosa Faner; Eddie James; Laurie Huston; Ricardo Pujol-Borrel; William W Kwok; Manel Juan
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

6.  The structure of HLA-DR52c: comparison to other HLA-DRB3 alleles.

Authors:  Shaodong Dai; Frances Crawford; Philippa Marrack; John W Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

Review 7.  HLA-DR: molecular insights and vaccine design.

Authors:  Lawrence J Stern; J Mauricio Calvo-Calle
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.

Authors:  D J Jackson; J L Eastlake; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

9.  Flanking p10 contribution and sequence bias in matrix based epitope prediction: revisiting the assumption of independent binding pockets.

Authors:  Christian S Parry
Journal:  BMC Struct Biol       Date:  2008-10-16

10.  A splice acceptor variant in HLA-DRA affects the conformation and cellular localization of the class II DR alpha-chain.

Authors:  Alessandro Didonna; Vincent Damotte; Hengameh Shams; Atsuko Matsunaga; Stacy J Caillier; Ravi Dandekar; Maneesh K Misra; Mohammad R K Mofrad; Jorge R Oksenberg; Jill A Hollenbach
Journal:  Immunology       Date:  2020-10-19       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.